ProSciento, OWL Metabolomics collaborate on NAFLD/NASH database

ProSciento and OWL Metabolomics have joined in an exclusive, multi-year collaboration aimed at identifying eligible individuals for clinical trials of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis therapeutic candidates, according to a press release.

“In recent years, advances in basic, clinical and regulatory science have led to a growing biopharmaceutical pipeline of NAFLD/NASH drug candidates, yet progress in translational research has been hindered in part by challenges in clinical trial recruitment,” Christian Weyer, MD, president and chief development officer of ProSciento said in the release. “OWL’s lipidomics-based assays ... hold great promise as a noninvasive method of identifying potential clinical research subjects and reducing screen failure rates.”

Under the terms of the agreement, the companies will establish a database of prospective trial participants using OWL Metabolomics’ diagnostic assays to evaluate for the presence of NAFLD and NASH. The initiative’s aim is to accelerate enrollment and reduce screen failure rates in fatty liver clinical trials.

The project will commence at ProSciento’s early phase clinical research unit and later integrate with the company’s network of metabolism-focused study sites. As part of the collaboration, OWL Metabolomics will join ProSciento’s Clinical Research Innovation partner network.

Reference : www.prosciento.com; www.owlmetabolomics.com